Adaptimmune Therapeutics PLC (NAS:ADAP)
$ 0.6984 -0.0248 (-3.43%) Market Cap: 178.71 Mil Enterprise Value: 73.46 Mil PE Ratio: 0 PB Ratio: 2.25 GF Score: 64/100

Q4 2020 Adaptimmune Therapeutics PLC Earnings Call Transcript

Feb 25, 2021 / 01:00PM GMT
Release Date Price: $5.94 (-0.83%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Adaptimmune conference call. With that, I'd like to turn the call over to Juli Miller. Ma'am, you may begin.

Juli P. Miller
Adaptimmune Therapeutics plc - Senior Director of IR

Good morning, and welcome to Adaptimmune's conference call to discuss our full year and fourth quarter 2020 financial results and business update. I would ask you to please review the full text of our forward-looking statements from this morning's press release. We anticipate making projections during this call and actual results could differ materially due to a number of factors, including those outlined in our latest filings with the SEC.

Adrian Rawcliffe, our Chief Executive Officer, is with me for the prepared portion of this call. Other members of our management team will be available for Q&A.

With that, I'll turn the call over to Adrian. Ad?

Adrian G. Rawcliffe
Adaptimmune Therapeutics plc - CEO, Principal Accounting Officer & Director

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot